EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 531.96 Thousand USD | -9.84% |
| 2022 | 590.04 Thousand USD | 312.17% |
| 2021 | 143.15 Thousand USD | 44.66% |
| 2020 | 98.96 Thousand USD | 0.57% |
| 2019 | 98.4 Thousand USD | 0.0% |
| 2017 | 1.38 Million USD | -89.59% |
| 2016 | 13.29 Million USD | 231.6% |
| 2015 | 4 Million USD | 130.86% |
| 2014 | 1.73 Million USD | 9.82% |
| 2013 | 1.58 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 52.59 Thousand USD | -72.54% |
| 2024 Q2 | 191.54 Thousand USD | 1610.11% |
| 2024 Q1 | 11.2 Thousand USD | -97.36% |
| 2023 FY | 531.96 Thousand USD | -9.84% |
| 2023 Q2 | 84.45 Thousand USD | 8.76% |
| 2023 Q4 | 424.7 Thousand USD | 96.72% |
| 2023 Q3 | 215.89 Thousand USD | 155.62% |
| 2023 Q1 | 77.65 Thousand USD | -85.17% |
| 2022 Q3 | 8963.00 USD | -74.0% |
| 2022 FY | 590.04 Thousand USD | 312.17% |
| 2022 Q2 | 34.47 Thousand USD | 0.0% |
| 2022 Q4 | 523.5 Thousand USD | 5740.7% |
| 2021 Q2 | 118.9 Thousand USD | -24.41% |
| 2021 FY | 143.15 Thousand USD | 44.66% |
| 2021 Q3 | 118.9 Thousand USD | 0.0% |
| 2021 Q1 | 157.29 Thousand USD | 0.0% |
| 2020 FY | 98.96 Thousand USD | 0.57% |
| 2019 FY | 98.4 Thousand USD | 0.0% |
| 2017 FY | 1.38 Million USD | -89.59% |
| 2017 Q4 | 12.03 Million USD | 0.0% |
| 2017 Q2 | 1.23 Million USD | 0.0% |
| 2017 Q1 | 1.23 Million USD | -44.43% |
| 2016 FY | 13.29 Million USD | 231.6% |
| 2016 Q4 | 2.21 Million USD | 11.52% |
| 2016 Q3 | 1.98 Million USD | -80.42% |
| 2016 Q2 | 10.14 Million USD | 1242.61% |
| 2016 Q1 | 755.62 Thousand USD | -48.59% |
| 2015 Q1 | 923.6 Thousand USD | -20.58% |
| 2015 Q4 | 1.46 Million USD | 59.2% |
| 2015 Q3 | 923.27 Thousand USD | -17.56% |
| 2015 FY | 4 Million USD | 130.86% |
| 2015 Q2 | 1.11 Million USD | 21.26% |
| 2014 Q4 | 1.16 Million USD | 44.9% |
| 2014 Q1 | 557.92 Thousand USD | -6.22% |
| 2014 Q2 | 156.07 Thousand USD | -72.03% |
| 2014 Q3 | 802.53 Thousand USD | 414.2% |
| 2014 FY | 1.73 Million USD | 9.82% |
| 2013 Q2 | 498.2 Thousand USD | 46.43% |
| 2013 Q1 | 340.24 Thousand USD | -9.94% |
| 2013 Q3 | 427.61 Thousand USD | -14.17% |
| 2013 FY | 1.58 Million USD | 0.0% |
| 2013 Q4 | 594.89 Thousand USD | 39.12% |
| 2012 Q4 | 377.77 Thousand USD | 99900.26% |
| 2012 Q3 | 377.78 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 60.166% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 89.449% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 98.2% |
| Nascent Biotech, Inc. | 2.22 Million USD | 76.144% |
| Rebus Holdings, Inc. | 664 Thousand USD | 19.885% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.572% |
| Qrons Inc. | 643.67 Thousand USD | 17.356% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -36.552% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.074% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -28.036% |
| Skye Bioscience, Inc. | 13.54 Million USD | 96.073% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.387% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 89.183% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -103.251% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.379% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 81.759% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 64.581% |
| Mesoblast Limited | 5.9 Million USD | 90.987% |
| Marizyme, Inc. | 19.23 Million USD | 97.235% |
| Genus plc | 147.7 Million USD | 99.64% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 93.941% |
| Pharming Group N.V. | 225.49 Million USD | 99.764% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 74.034% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 60.347% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 93.621% |
| ContraFect Corporation | 56.88 Million USD | 99.065% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 87.934% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 64.026% |
| IMV Inc. | 37.7 Million USD | 98.589% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 80.936% |
| MultiCell Technologies, Inc. | 567.42 USD | -93651.013% |
| ONE Bio Corp. | 6.44 Million USD | 91.745% |
| Accustem Sciences Inc. | 3.74 Million USD | 85.801% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.381% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | 3.43 Million USD | 84.521% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.848% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 79.754% |
| Biomind Labs Inc. | 994.18 Thousand USD | 46.492% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.464% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 69.769% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 92.082% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 71.467% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2227.848% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 96.677% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 71.012% |
| GB Sciences, Inc. | 1.42 Million USD | 62.551% |
| Alpha Cognition Inc. | 9.7 Million USD | 94.519% |
| HST Global, Inc. | 140.9 Thousand USD | -277.527% |
| CSL Limited | 3.44 Billion USD | 99.985% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 52.711% |
| Halberd Corporation | 74.84 Thousand USD | -610.78% |
| Enzolytics Inc. | 2.17 Million USD | 75.593% |
| Agentix Corp. | 1.37 Million USD | 61.22% |
| Resverlogix Corp. | 12.71 Million USD | 95.815% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 85.429% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.965% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 49.046% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 77.88% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 66.318% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 84.377% |
| AVAX Technologies, Inc. | 7.31 Million USD | 92.723% |
| Zenith Capital Corp. | 8.94 Million USD | 94.052% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.936% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2953.568% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 78.334% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -210.166% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 72.307% |
| Kadimastem Ltd | 2.41 Million USD | 77.928% |
| Helix BioMedix, Inc. | 1.97 Million USD | 73.025% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 95.105% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.685% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -193.116% |
| LadRx Corporation | 3.81 Million USD | 86.044% |
| Cell Source, Inc. | 4.32 Million USD | 87.701% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 42.398% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 42.398% |
| NovAccess Global Inc. | 2.46 Million USD | 78.435% |
| Affymax, Inc. | 39.38 Million USD | 98.649% |
| Itoco Inc. | 919.14 Thousand USD | 42.124% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 87.449% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 52.461% |
| Mobile Lads Corp. | 554.54 Thousand USD | 4.073% |
| CytoDyn Inc. | 18.05 Million USD | 97.054% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2013.56% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -141.715% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 62.532% |
| SYBLEU INC | 160.87 Thousand USD | -230.666% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 70.712% |
| International Stem Cell Corporation | 5.27 Million USD | 89.908% |
| Bioxytran, Inc. | 3.82 Million USD | 86.075% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -910.528% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -2514.963% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.533% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 67.122% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 27.706% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 82.901% |
| Neutra Corp. | 243.82 Thousand USD | -118.177% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 96.953% |
| PureTech Health plc | 144.59 Million USD | 99.632% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 97.404% |
| IXICO plc | 4.7 Million USD | 88.698% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 93.953% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.548% |
| CSL Limited | 3.89 Billion USD | 99.986% |
| Cellectis S.A. | 97.32 Million USD | 99.453% |